Multihance is a brand name of gadobenate dimeglumine, approved by the FDA in the following formulation(s):
MULTIHANCE (gadobenate dimeglumine - injectable; intravenous)
Manufacturer: BRACCO
Approval date: November 23, 2004
Strength(s): 10.58GM/20ML (529MG/ML) [RLD], 2.645GM/5ML (529MG/ML) [RLD], 5.29GM/10ML (529MG/ML) [RLD], 7.935GM/15ML (529MG/ML) [RLD]
Has a generic version of Multihance been approved?
No. There is currently no therapeutically equivalent version of Multihance available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Multihance. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Paramagnetic chelates useful for NMR imaging
Patent 4,916,246
Issued: April 10, 1990
Inventor(s): Felder; Ernst & Uggeri; Fulvio & Fumagalli; Luciano & Vittadini; Giorgio
Assignee(s): Bracco Chimica S.p.A.
Compounds suitable for NMR imaging having the formula: ##STR1## wherein a is 2 or 3; b is an integer from 0 to 4; Me.sup.(a+) is Fe.sup.(2+), Fe.sup.(3+), Gd.sup.(3+), or Mn.sup.(2+) ; E.sup.(b+) is an ion of an alkali metal, alkaline earth metal, alkyl ammonium, alkanol ammonium, polyhydroxyalkyl ammonium, or basic protonated amino acid, said ions representing a total charge of b; m is an integer from 1 to 5; R is H, alkyl with from 1 to 8 carbon atoms, alkyl with from 1 to 8 carbon atoms wherein from 1 to 5 carbons are substituted with OH; aralkyl with 1 to 4 aliphatic carbon atoms; phenyl or phenyl substituted by halogen, hydroxyl, carboxyl, carboxamide, ester, SO.sub.3 H, sulfonamide, lower alkyl, lower hydroxy alkyl, amino, acylamino; (poly)oxa-alkyl with 1 to 50 oxygen atoms and from 3 to 150 carbon atoms, wherein 1 to 5 hydrogen atoms may be substituted by OH; R.sub.1 is the same as R.sub.2 or is --CH.sub.2 COOZ, --CH(CH.sub.3)COOZ, CH.sub.2 CH.sub.2 --N(CH.sub.2 COOZ).sub.2, a hydroxy arylalkyl, hydroxy pyridylalkyl, hydroxy aryl(carboxy)alkyl or hydroxy pyridyl-(carboxy)alkyl radical, where the aryl or pyridyl radical may be substituted by hydroxyl, hydroxy alkyl, alkyl, halogen, carboxyl or SO.sub.3 H; R.sub.2 is --CH.sub.2 COOZ, --CH(CH.sub.3)COOZ, ##STR2## wherein R.sub.3 is --CH.sub.2 COOZ, --CH(CH.sub.3)COOZ or a monovalent radical having the structure ##STR3## X is a direct chemical bond, --O--, --S--, --NH--, ##STR4## n is the integer 2 or 3, with the proviso that when X represents a direct bond, n is 1, 2 or 3; Z is hydrogen or a unit of negative charge, and --(CH.sub.2).sub.m -- may also be --CH.sub.2 --C(CH.sub.3).sub.2 --.
Patent expiration dates:
- April 10, 2012
✓
Drug substance
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
See also...
- Multihance Consumer Information (Cerner Multum)
- Multihance Advanced Consumer Information (Micromedex)
- Gadobenate dimeglumine Consumer Information (Cerner Multum)
- Gadobenate Intravenous Advanced Consumer Information (Micromedex)
